膀胱内灌注治疗复发性尿路感染:系统综述与荟萃分析
该系统综述与荟萃分析纳入25项研究,评估膀胱内灌注预防复发性尿路感染(rUTI)的疗效与安全性。氨基糖苷类灌注显著降低复发(合并IRR 0.23,95%CI 0.15-0.37,P<0.001),透明质酸(HA)单药也有效(合并RR 0.15,95%CI 0.05-0.43,P=0.011),HA+硫酸软骨素(CS)合并效应不精确。灌注总体安全,不良事件轻微。
要点
- 氨基糖苷类膀胱灌注可显著降低rUTI复发风险。
- HA单药为有效的非抗生素灌注选择。
- HA+CS联合治疗证据不足,需进一步研究。
核心结论
- 膀胱内灌注对特定rUTI患者安全有效,最强证据支持氨基糖苷类,HA提供非抗生素替代。
研究设计与样本
- 系统综述与荟萃分析,检索2000年1月至2025年4月PubMed/MEDLINE、Embase、Cochrane CENTRAL、Scopus和Web of Science,纳入25项随机和观察性研究。
主要发现
- 氨基糖苷类灌注合并IRR 0.23(95%CI 0.15-0.37;P<0.001),在神经源性和非神经源性人群及庆大霉素和阿米卡星中一致有益。
- HA单药合并RR 0.15(95%CI 0.05-0.43;P=0.011),但异质性高。
- HA+CS联合治疗合并RR 0.41(95%CI 0.04-4.77;P=0.465),效应不精确。
- 肝素、聚维酮碘和磷霉素的叙述性证据提示潜在益处,但方法和结局定义不一致。
- 测定的血清氨基糖苷水平未检出,不良事件轻微且不常见。
关键数值与推荐
- 主要结局为UTI复发,以发病率比(IRR)或风险比(RR)表示。
- 对氨基糖苷类、HA单药和HA+CS联合治疗三个干预家族进行随机效应荟萃分析。
- 亚组分析考察人群类型和所用抗生素;敏感性分析包括留一法重新估计。
临床怎么用
- 对于特定rUTI患者,可考虑膀胱内灌注氨基糖苷类或HA以预防复发。
- HA+CS联合治疗暂不作为常规推荐,需更多高质量研究。
局限性
- HA单药分析异质性高。
- HA+CS联合治疗合并效应不精确。
- 肝素、聚维酮碘和磷霉素证据方法和结局定义不一致。
- 需要更大规模、高质量、标准结局的随机试验优化方案和患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To undertake a systematic review and meta-analysis to evaluate the efficacy, safety, and clinical applicability of intravesical instillations for preventing recurrent urinary tract infections (rUTIs). METHODS: PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, and Web of Science were searched from January 2000 to April 2025 for randomised and observational studies of intravesical instillations in rUTI treatment. The primary outcome was UTI recurrence, expressed as incidence rate ratio (IRR) or risk ratio (RR). Random-effects meta-analyses were performed for three intervention families: aminoglycosides, hyaluronic acid (HA) monotherapy, and HA with chondroitin sulphate (HA + CS) combined therapy. Subgroup analyses examined population type and antibiotic used; sensitivity analyses included leave-one-out re-estimation. Other agents were narratively synthesised. RESULTS: Total of 25 studies were included. Aminoglycoside instillations produced a marked reduction in recurrence (pooled IRR 0.23, 95% confidence interval [CI] 0.15-0.37; P < 0.001), with consistent benefit across neurogenic and non-neurogenic populations and across gentamicin and amikacin. HA monotherapy was also effective (pooled RR 0.15, 95% CI 0.05-0.43; P = 0.011), although heterogeneity was high. HA + CS combined therapy showed favourable results in individual studies but an imprecise pooled effect (RR 0.41, 95% CI 0.04-4.77; P = 0.465). Narrative evidence for heparin, povidone-iodine and fosfomycin suggested potential benefit, but methods and outcome definitions were inconsistent. Serum aminoglycoside levels were undetectable where measured, and adverse events were mild and infrequent. CONCLUSION: Intravesical instillations appear safe and effective for preventing rUTIs in select patients. The strongest evidence supports aminoglycosides while HA offers a non-antibiotic alternative. HA + CS requires further study. Larger, high-quality randomised trials with standardised outcomes are needed to optimise protocols and patient selection.
引用
- Kwon M, Ahmad A, Lott N, et al. Intravesical therapy for recurrent urinary tract infection: a systematic review and meta-analysis. BJU Int. 2026. PMID: 41858162. doi:10.1111/bju.70252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。